Valuation : Immatics N.V.

Market Cap 1.29B 1.11B 1.04B 953M 1.79B 123B 1.8B 12.38B 4.83B 62.32B 4.85B 4.74B 207B P/E 2026 *
-4.47x
P/E 2027 * -4.49x
Enterprise Value 1.01B 866M 812M 742M 1.4B 96.1B 1.4B 9.64B 3.76B 48.51B 3.78B 3.69B 161B EV / Sales 2026 *
21.6x
EV / Sales 2027 * 24.1x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day+0.96%
1 week+5.82%
Current month+9.12%
1 month+2.72%
3 months-17.90%
6 months-5.41%
Current year-10.00%
1 week 8.97
Extreme 8.97
9.89
1 month 8.37
Extreme 8.37
9.98
Current year 8.17
Extreme 8.17
11.94
1 year 5.05
Extreme 5.05
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
16.3
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Date Insider Type Main position Quantity % Market Cap.
26/8/26
Perceptive Advisors LLC
BuyCompany 863,060 0.6436%
18/3/26 Other

Chief Financial Officer

350,000 0.2611%
18/3/26 Other

Head of Human Resources

211,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
+0.96%+5.82%+85.66%-21.25% 1.29B
-1.59%-3.35%+52.37%+91.62% 69.54B
-1.97%+1.55%+44.87%+88.81% 64.97B
-3.57%+0.49%+35.74%+10.62% 26.51B
-2.35%-5.75%-12.90%+436.87% 25.89B
-8.37%-12.43%+2.08%-18.39% 25.64B
-0.96%+10.36%+283.06%+429.04% 20.22B
-1.14%+0.90%+29.90%-19.28% 19.98B
-3.36%-4.93%+2.30%+549.93% 15.69B
-1.47%+0.68%+45.51%+142.00% 13.49B
Average -2.38%-1.15%+56.86%+169.00% 28.32B
Weighted average by Cap. -2.55%-1.47%+50.51%+148.52%

Financials

2026 *2027 *
Net sales 46.54M 40.1M 37.6M 34.32M 64.66M 4.45B 64.87M 446M 174M 2.25B 175M 171M 7.44B 39.58M 34.11M 31.98M 29.19M 54.99M 3.78B 55.17M 379M 148M 1.91B 149M 145M 6.33B
Net income -287M -248M -232M -212M -399M -27.47B -401M -2.75B -1.07B -13.87B -1.08B -1.06B -45.98B -310M -267M -250M -228M -430M -29.59B -432M -2.97B -1.16B -14.94B -1.16B -1.14B -49.53B
Net Debt -286M -247M -231M -211M -398M -27.35B -399M -2.74B -1.07B -13.81B -1.07B -1.05B -45.78B -339M -292M -274M -250M -471M -32.37B -472M -3.25B -1.27B -16.34B -1.27B -1.24B -54.18B
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
28/08/26 US$9.450 +0.96% 1,094,155
27/08/26 US$9.360 -0.74% 743,417
26/08/26 US$9.430 +2.06% 777,957
25/08/26 US$9.240 +6.33% 1,062,766
24/08/26 US$8.690 -2.69% 338,149
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.450USD
Average target price
17.63USD
Spread / Average Target
+86.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock